Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: Results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Nicola Di Renzo, Antonella Montanini, Donato Mannina, Alessandra Dondi, Stefania Muci, Salvatrice Mancuso, M. Rosaria De Paolis, Caterina Plati, Caterina Stelitano, Catia Patti, Attilio Olivieri, Eliana Liardo, Gabriele Buda, Renato Cantaffa, Massimo Federico

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT 3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. Methods: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint. Results: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%. Conclusions: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids.

Original languageEnglish
Pages (from-to)1505-1510
Number of pages6
JournalSupportive Care in Cancer
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2011

Keywords

  • CHOP
  • CINV
  • Emesis
  • Nausea
  • NHL
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: Results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)'. Together they form a unique fingerprint.

Cite this